12:00 AM
 | 
Mar 15, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Exelon rivastigmine: Phase III data; marketed in EU

Researchers published data from a 725-patient trial in the British Medical Journal showing that patients receiving 12 mg/day of Exelon had a statistically significant...

Read the full 100 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >